 Todd Bradley
Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 21 | 2022 | 31 | 5.520 |
Why?
| | Antibodies, Neutralizing | 17 | 2022 | 31 | 4.880 |
Why?
| | HIV Infections | 18 | 2023 | 140 | 4.420 |
Why?
| | AIDS Vaccines | 17 | 2020 | 18 | 4.410 |
Why?
| | HIV Antibodies | 16 | 2021 | 16 | 3.690 |
Why?
| | Antibodies, Viral | 8 | 2022 | 46 | 2.580 |
Why?
| | Spike Glycoprotein, Coronavirus | 5 | 2022 | 19 | 2.240 |
Why?
| | Humans | 41 | 2024 | 6599 | 1.810 |
Why?
| | Viral Vaccines | 2 | 2022 | 10 | 1.770 |
Why?
| | Animals | 26 | 2024 | 563 | 1.740 |
Why?
| | B-Lymphocytes | 11 | 2021 | 23 | 1.670 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 8 | 2021 | 8 | 1.630 |
Why?
| | Vaccination | 7 | 2022 | 68 | 1.600 |
Why?
| | Macaca mulatta | 15 | 2024 | 22 | 1.400 |
Why?
| | HIV Envelope Protein gp120 | 7 | 2021 | 7 | 1.340 |
Why?
| | HIV Envelope Protein gp41 | 3 | 2016 | 3 | 1.320 |
Why?
| | Simian Immunodeficiency Virus | 5 | 2023 | 5 | 1.090 |
Why?
| | Killer Cells, Natural | 5 | 2021 | 12 | 1.070 |
Why?
| | Immunity, Humoral | 3 | 2022 | 14 | 1.070 |
Why?
| | Immunity, Innate | 3 | 2021 | 16 | 0.970 |
Why?
| | Epitopes | 8 | 2022 | 19 | 0.950 |
Why?
| | Lactation | 1 | 2023 | 5 | 0.930 |
Why?
| | Milk, Human | 1 | 2023 | 21 | 0.920 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 11 | 0.890 |
Why?
| | Female | 16 | 2023 | 3436 | 0.860 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2020 | 34 | 0.840 |
Why?
| | Neoplasms | 2 | 2021 | 119 | 0.820 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 2 | 0.790 |
Why?
| | Adaptive Immunity | 1 | 2020 | 5 | 0.760 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 71 | 0.750 |
Why?
| | Immunologic Factors | 1 | 2020 | 1 | 0.750 |
Why?
| | RNA, Messenger | 3 | 2021 | 107 | 0.740 |
Why?
| | HIV | 2 | 2023 | 7 | 0.740 |
Why?
| | Transcriptome | 6 | 2022 | 50 | 0.700 |
Why?
| | Middle Aged | 7 | 2021 | 648 | 0.700 |
Why?
| | Mice | 8 | 2022 | 290 | 0.680 |
Why?
| | Adult | 9 | 2022 | 1233 | 0.680 |
Why?
| | Male | 15 | 2021 | 3197 | 0.660 |
Why?
| | Hydrolases | 1 | 2016 | 1 | 0.600 |
Why?
| | Tryptophan | 1 | 2016 | 4 | 0.600 |
Why?
| | Peptides | 1 | 2016 | 9 | 0.590 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 2 | 0.590 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2022 | 11 | 0.590 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 9 | 0.590 |
Why?
| | Single-Cell Analysis | 3 | 2022 | 9 | 0.580 |
Why?
| | Mutation | 7 | 2019 | 194 | 0.560 |
Why?
| | Polyadenylation | 1 | 2014 | 2 | 0.520 |
Why?
| | RNA-Binding Proteins | 1 | 2014 | 5 | 0.520 |
Why?
| | RNA Splicing | 1 | 2014 | 11 | 0.520 |
Why?
| | Heart Failure | 2 | 2012 | 14 | 0.520 |
Why?
| | Immunization | 7 | 2020 | 23 | 0.500 |
Why?
| | Transcription, Genetic | 3 | 2020 | 44 | 0.480 |
Why?
| | Viremia | 2 | 2023 | 3 | 0.450 |
Why?
| | Antibody Affinity | 3 | 2022 | 4 | 0.440 |
Why?
| | Fluid Shifts | 1 | 2012 | 1 | 0.440 |
Why?
| | Edema | 1 | 2012 | 8 | 0.440 |
Why?
| | Circadian Rhythm | 1 | 2012 | 8 | 0.440 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 9 | 0.430 |
Why?
| | Child | 6 | 2023 | 3146 | 0.430 |
Why?
| | Disease Models, Animal | 3 | 2023 | 55 | 0.420 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 2 | 2023 | 3 | 0.410 |
Why?
| | Protein Binding | 5 | 2017 | 30 | 0.380 |
Why?
| | Polysaccharides | 2 | 2021 | 2 | 0.360 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 27 | 0.350 |
Why?
| | Cross Reactions | 2 | 2021 | 7 | 0.350 |
Why?
| | Host-Pathogen Interactions | 2 | 2021 | 8 | 0.350 |
Why?
| | Vaccines | 3 | 2021 | 17 | 0.350 |
Why?
| | Infant | 3 | 2023 | 1396 | 0.340 |
Why?
| | Neutralization Tests | 3 | 2017 | 6 | 0.340 |
Why?
| | Antibodies, Blocking | 2 | 2020 | 3 | 0.330 |
Why?
| | Cell Line | 3 | 2018 | 80 | 0.320 |
Why?
| | Aged | 3 | 2021 | 375 | 0.310 |
Why?
| | Immunoglobulin G | 3 | 2024 | 33 | 0.300 |
Why?
| | Epitope Mapping | 3 | 2021 | 7 | 0.290 |
Why?
| | Animals, Newborn | 2 | 2023 | 23 | 0.290 |
Why?
| | Gene Expression Regulation | 3 | 2021 | 98 | 0.280 |
Why?
| | Cytokines | 2 | 2023 | 48 | 0.280 |
Why?
| | Young Adult | 4 | 2022 | 652 | 0.270 |
Why?
| | Antibody Specificity | 2 | 2021 | 8 | 0.260 |
Why?
| | Phagocytosis | 3 | 2021 | 3 | 0.250 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 14 | 0.250 |
Why?
| | Peptide Fragments | 2 | 2021 | 12 | 0.250 |
Why?
| | Receptors, IgG | 1 | 2024 | 1 | 0.240 |
Why?
| | Antigen-Antibody Complex | 1 | 2024 | 2 | 0.240 |
Why?
| | Adolescent | 5 | 2022 | 2087 | 0.240 |
Why?
| | Immunotherapy | 2 | 2020 | 14 | 0.240 |
Why?
| | Immunoglobulins | 1 | 2023 | 5 | 0.230 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 7 | 0.230 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2020 | 3 | 0.230 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2023 | 11 | 0.230 |
Why?
| | Viral Envelope Proteins | 2 | 2020 | 3 | 0.230 |
Why?
| | Mice, Transgenic | 2 | 2020 | 33 | 0.220 |
Why?
| | Phylogeny | 3 | 2017 | 21 | 0.220 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 9 | 0.220 |
Why?
| | Child, Preschool | 3 | 2022 | 1459 | 0.220 |
Why?
| | HEK293 Cells | 2 | 2018 | 30 | 0.210 |
Why?
| | Survivors | 1 | 2021 | 17 | 0.210 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 109 | 0.210 |
Why?
| | Recombinant Proteins | 2 | 2021 | 47 | 0.210 |
Why?
| | Molecular Sequence Data | 3 | 2016 | 65 | 0.210 |
Why?
| | Nasal Mucosa | 1 | 2021 | 8 | 0.210 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2021 | 1 | 0.200 |
Why?
| | Phosphoproteins | 1 | 2021 | 11 | 0.200 |
Why?
| | Immune Evasion | 2 | 2021 | 3 | 0.200 |
Why?
| | Vaccine Potency | 1 | 2021 | 7 | 0.200 |
Why?
| | Plasmodium falciparum | 1 | 2021 | 1 | 0.200 |
Why?
| | Malaria, Falciparum | 1 | 2021 | 1 | 0.200 |
Why?
| | Malaria Vaccines | 1 | 2021 | 2 | 0.200 |
Why?
| | Antibodies, Protozoan | 1 | 2021 | 3 | 0.200 |
Why?
| | Vaccines, Subunit | 2 | 2021 | 3 | 0.200 |
Why?
| | Rituximab | 1 | 2021 | 3 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2022 | 14 | 0.200 |
Why?
| | Cyclophosphamide | 1 | 2021 | 8 | 0.200 |
Why?
| | Datasets as Topic | 1 | 2021 | 7 | 0.200 |
Why?
| | Vincristine | 1 | 2021 | 8 | 0.200 |
Why?
| | Prednisone | 1 | 2021 | 12 | 0.200 |
Why?
| | Doxorubicin | 1 | 2021 | 17 | 0.200 |
Why?
| | Liver Transplantation | 1 | 2021 | 43 | 0.200 |
Why?
| | Sarcoma | 1 | 2020 | 6 | 0.200 |
Why?
| | Carrier Proteins | 1 | 2021 | 32 | 0.200 |
Why?
| | Survival Rate | 1 | 2021 | 84 | 0.200 |
Why?
| | Case-Control Studies | 1 | 2021 | 202 | 0.200 |
Why?
| | Biomarkers | 1 | 2021 | 120 | 0.190 |
Why?
| | Polysomnography | 2 | 2012 | 14 | 0.190 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 76 | 0.190 |
Why?
| | Age Factors | 1 | 2021 | 203 | 0.190 |
Why?
| | Prognosis | 1 | 2021 | 209 | 0.190 |
Why?
| | Receptors, OX40 | 1 | 2020 | 1 | 0.190 |
Why?
| | CTLA-4 Antigen | 1 | 2020 | 3 | 0.190 |
Why?
| | Molecular Mimicry | 2 | 2016 | 2 | 0.190 |
Why?
| | Selection, Genetic | 1 | 2019 | 2 | 0.180 |
Why?
| | HLA-DQ beta-Chains | 1 | 2019 | 2 | 0.180 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 5 | 0.180 |
Why?
| | Virus Latency | 1 | 2018 | 1 | 0.170 |
Why?
| | Proviruses | 1 | 2018 | 2 | 0.170 |
Why?
| | Jurkat Cells | 1 | 2018 | 4 | 0.170 |
Why?
| | Down-Regulation | 1 | 2018 | 14 | 0.170 |
Why?
| | RNA, Viral | 1 | 2018 | 16 | 0.170 |
Why?
| | Antibodies | 1 | 2018 | 15 | 0.170 |
Why?
| | Guanidines | 1 | 2018 | 1 | 0.170 |
Why?
| | Indenes | 1 | 2018 | 1 | 0.170 |
Why?
| | Lentiviruses, Primate | 1 | 2018 | 1 | 0.170 |
Why?
| | Epitopes, B-Lymphocyte | 2 | 2016 | 2 | 0.170 |
Why?
| | Immunization, Secondary | 1 | 2018 | 2 | 0.160 |
Why?
| | Prospective Studies | 3 | 2022 | 508 | 0.160 |
Why?
| | Infant, Newborn | 1 | 2021 | 790 | 0.160 |
Why?
| | Cohort Studies | 1 | 2018 | 264 | 0.160 |
Why?
| | Complement System Proteins | 1 | 2017 | 5 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 11 | 0.150 |
Why?
| | Regression Analysis | 1 | 2017 | 56 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2021 | 142 | 0.150 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 99 | 0.150 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 1 | 0.150 |
Why?
| | Biomimetics | 1 | 2016 | 1 | 0.150 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 14 | 0.150 |
Why?
| | Antigenic Variation | 1 | 2016 | 1 | 0.150 |
Why?
| | Mice, Knockout | 1 | 2016 | 54 | 0.150 |
Why?
| | Gene Expression | 1 | 2016 | 60 | 0.140 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 36 | 0.140 |
Why?
| | Immunoglobulin Light Chains | 1 | 2014 | 2 | 0.130 |
Why?
| | Consensus Sequence | 1 | 2014 | 3 | 0.130 |
Why?
| | Drosophila melanogaster | 1 | 2014 | 4 | 0.130 |
Why?
| | RNA Stability | 1 | 2014 | 4 | 0.130 |
Why?
| | Binding Sites | 1 | 2014 | 26 | 0.130 |
Why?
| | Models, Molecular | 3 | 2021 | 14 | 0.130 |
Why?
| | Base Sequence | 1 | 2014 | 76 | 0.130 |
Why?
| | Promoter Regions, Genetic | 1 | 2014 | 47 | 0.130 |
Why?
| | Argonaute Proteins | 1 | 2013 | 1 | 0.110 |
Why?
| | Drosophila | 1 | 2013 | 4 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2013 | 6 | 0.110 |
Why?
| | Drosophila Proteins | 1 | 2013 | 7 | 0.110 |
Why?
| | Alternative Splicing | 1 | 2013 | 17 | 0.110 |
Why?
| | Ontario | 1 | 2012 | 2 | 0.110 |
Why?
| | Neck | 1 | 2012 | 5 | 0.110 |
Why?
| | Lower Extremity | 1 | 2012 | 6 | 0.110 |
Why?
| | Linear Models | 1 | 2012 | 55 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2012 | 74 | 0.110 |
Why?
| | Immunity, Cellular | 2 | 2022 | 18 | 0.110 |
Why?
| | Sex Factors | 1 | 2012 | 71 | 0.110 |
Why?
| | Risk Assessment | 1 | 2012 | 130 | 0.100 |
Why?
| | Time Factors | 1 | 2012 | 241 | 0.100 |
Why?
| | Viral Load | 2 | 2021 | 20 | 0.100 |
Why?
| | Risk Factors | 1 | 2012 | 460 | 0.100 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2021 | 2 | 0.100 |
Why?
| | Binding Sites, Antibody | 2 | 2021 | 4 | 0.090 |
Why?
| | Immune Tolerance | 2 | 2021 | 8 | 0.090 |
Why?
| | Sleep Apnea, Central | 1 | 2009 | 2 | 0.090 |
Why?
| | Gene Knock-In Techniques | 2 | 2019 | 4 | 0.090 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2009 | 3 | 0.090 |
Why?
| | Mice, Mutant Strains | 2 | 2019 | 7 | 0.080 |
Why?
| | RNA Polymerase I | 1 | 2007 | 1 | 0.080 |
Why?
| | Ribonucleoproteins, Small Nuclear | 1 | 2007 | 1 | 0.080 |
Why?
| | Antibodies, Antinuclear | 1 | 2007 | 3 | 0.080 |
Why?
| | Autoantigens | 1 | 2007 | 5 | 0.080 |
Why?
| | Cell Lineage | 2 | 2017 | 17 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2007 | 14 | 0.070 |
Why?
| | Frameshift Mutation | 1 | 2024 | 5 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 11 | 0.060 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 23 | 0.060 |
Why?
| | Immunoglobulin Fragments | 1 | 2021 | 1 | 0.050 |
Why?
| | Genes, env | 1 | 2021 | 1 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2021 | 4 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2021 | 7 | 0.050 |
Why?
| | Glycosylation | 1 | 2021 | 1 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2021 | 31 | 0.050 |
Why?
| | Dimerization | 1 | 2021 | 3 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 3 | 0.050 |
Why?
| | Lipid A | 1 | 2021 | 1 | 0.050 |
Why?
| | Saponins | 1 | 2021 | 1 | 0.050 |
Why?
| | Interleukin-5 | 1 | 2021 | 1 | 0.050 |
Why?
| | Th2 Cells | 1 | 2021 | 1 | 0.050 |
Why?
| | Receptors, CXCR5 | 1 | 2021 | 1 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2021 | 4 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2021 | 6 | 0.050 |
Why?
| | Adenoviridae | 1 | 2021 | 6 | 0.050 |
Why?
| | Vaccinia virus | 1 | 2021 | 4 | 0.050 |
Why?
| | Tumor Escape | 1 | 2020 | 1 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 3 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2020 | 5 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 17 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 35 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 27 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 51 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 1 | 0.050 |
Why?
| | Antibody Formation | 1 | 2020 | 4 | 0.050 |
Why?
| | Monocytes | 1 | 2020 | 9 | 0.050 |
Why?
| | Up-Regulation | 1 | 2020 | 25 | 0.050 |
Why?
| | Microbiota | 1 | 2020 | 8 | 0.050 |
Why?
| | Macaca | 1 | 2019 | 2 | 0.050 |
Why?
| | Feces | 1 | 2020 | 37 | 0.050 |
Why?
| | Virus Replication | 1 | 2019 | 6 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2019 | 6 | 0.040 |
Why?
| | HIV Seropositivity | 1 | 2019 | 8 | 0.040 |
Why?
| | Drug Administration Routes | 1 | 2018 | 3 | 0.040 |
Why?
| | Primates | 1 | 2018 | 2 | 0.040 |
Why?
| | Injections, Intramuscular | 1 | 2018 | 5 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2018 | 19 | 0.040 |
Why?
| | Immunity, Heterologous | 1 | 2018 | 1 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 9 | 0.040 |
Why?
| | Cytidine Deaminase | 1 | 2018 | 1 | 0.040 |
Why?
| | Mutation Rate | 1 | 2018 | 2 | 0.040 |
Why?
| | Probability | 1 | 2018 | 17 | 0.040 |
Why?
| | Clonal Anergy | 1 | 2017 | 1 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2017 | 4 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2016 | 26 | 0.040 |
Why?
| | Haplorhini | 1 | 2016 | 2 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2016 | 5 | 0.040 |
Why?
| | Sequence Alignment | 1 | 2016 | 9 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 23 | 0.040 |
Why?
| | Protein Engineering | 1 | 2014 | 3 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2014 | 5 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2014 | 73 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 44 | 0.030 |
Why?
| | RNA | 1 | 2013 | 14 | 0.030 |
Why?
| | Chromatin | 1 | 2013 | 20 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2009 | 315 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2007 | 1 | 0.020 |
Why?
| | snRNP Core Proteins | 1 | 2007 | 2 | 0.020 |
Why?
| | Ribonucleoproteins | 1 | 2007 | 2 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 5 | 0.020 |
Why?
| | Autoimmunity | 1 | 2007 | 2 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 25 | 0.020 |
Why?
| | Rats | 1 | 2007 | 97 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|